Intelerad workflow solution to include Zebra Medical Vision’s AI offerings

Intelerad Medical Systems and Zebra Medical Vision have announced a new partnership involving Intelerad’s Odyssey workflow management solution.

As a part of this arrangement, Zebra-Med’s bundle of AI solutions, AI1, will now be included as a primary building block of Odyssey. The move, according to a prepared statement from both companies, is “designed to encourage the adoption of artificial intelligence without the prohibitive costs usually associated with such programs.”

Odyssey also charges users per study, a feature put in place to keep costs down for providers who may not want to pay a flat fee right off the bat. A 12-month trial is also being offered to celebrate the release of Odyssey, an offer only available “for a limited time.”

“Odyssey will deliver state-of-the-art clinical AI solutions directly integrated into the radiologists’ natural workflow and tailored to the needs of individual organizations,” Chris Wood, chief technology officer at Intelerad, said in the prepared statement. “With Zebra-Med’s AI1, we are committed to providing a broad and growing portfolio of high-value, innovative technology solutions to our customers and this unprecedented approach to artificial intelligence in radiology will extend our leadership position in workflow management.”

“We are excited to be supporting Intelerad’s team and the 300 healthcare organizations they serve, with our ‘all-in-one’ AI1 ever-growing portfolio of FDA-cleared AI products,“ Eyal Gura, CEO of Zebra Medical Vision, said in the same statement. “We are committed to bring more AI value in an integrated way to the workflow and in all modalities.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.